The need for genetic studies of Indigenous Australians
Author: Gareth S Baynam
Published online: 19 March 2012
To the Editor: The continuing integration of genetic technologies into clinical medicine is providing opportunities for health care improvement. This has the potential to reduce health disparities between Indigenous and non-Indigenous Australians in several ways: improving our understanding of disease pathogenesis, obtaining a perspective from which to view environmental risks, improving prediction of disease risk, identifying new diagnostic techniques and drug targets, and making advances in pharmacogenomics.
Unfortunately, the dearth of genetic research involving Indigenous Australians may exclude them from such benefits of biomedical innovation.1 This is beginning to affect the clinical utility of genetic tests. For instance, in selected circumstances, single nucleotide polymorphism chromosomal microarrays (CMAs), which examine one’s chromosomal constitution at high resolution, are being employed to investigate a variety of phenotypes. To interpret the results of genetic investigations such as CMAs, it is a critical to understand the range of normal genetic variation, which is partly population specific. In addition, technologies such as next-generation sequencing, which can be used to analyse an individual’s exome or genome, will soon be used in clinical care. A survey conducted by Nature suggests that the current bias against studies of non-European people is likely to pervade these techniques.2 If so, a biased picture of which variants are important will emerge and, globally, genomic medicine will largely benefit a privileged (European) few.3 Notably, rare genetic variants (ie, those occurring in less than 5% of the world’s population) are disproportionately important in terms of complex disease risk and pharmacogenomics,4 and some are the cause of monogenic disease. Rare variations tend to be population specific. Accordingly, reference data from historically marginalised populations are needed to separate real from spurious findings.3 In addition, to help determine the significance of genotypic variation, there is a parallel need for accurate phenotypic information. Therefore, genetic studies will need to be coupled with detailed phenotyping, for which high-throughput phenomic assessments may be required.
Advances in genetic testing that will be used for clinical care therefore require engagement of Indigenous communities, so that normal genetic variation in these populations can be ascertained. To maximise benefit and minimise harm, this will need to be managed in an inclusive and culturally sensitive manner, with open discussion among all relevant parties.1 Failure to prioritise Indigenous genetic studies may perpetuate health inequity.

Competing interests
References
- Kowal E, Rouhani L, Anderson I. Genetic research in Aboriginal and Torres Strait Islander communities: beginning the conversation. Melbourne: The Lowitja Institute, 2011. 0_CHDGJIEH
- Genomes by the thousand. Nature 2010; 467: 1026-1027. 0_i1142869
- Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature 2011; 475: 163-165. 0_i1142871
- Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753. 0_i1142874
Not Gone but Often Forgotten: Action Needed to Address Tuberculosis in Aboriginal and Torres Strait Islander Communities
Nikkita Joshua, Emma L. Smith, Eunice (Cheeky) Love, Christopher P. Lowbridge, Nicole Tukana, Amy Bowden, Megan A. Campbell, Dawn Casey, James Ward
Newborn Screening: Equity for Aboriginal and Torres Strait Islander Families in the Context of Emerging Genomics
Gail Garvey, Sarah Norris, Joanne Scarfe, Louise Lyons
Forty Years in the Making: Reporting on the Co-Creation of a National Roadmap for Birthing on Country Services for the Best Start to Life
Res McCalman, Anneka J. Bowman, Roianne West, Kristie Watego, Jyai Allen, Claire Clack, Sue Kildea, Sue Kruske, Melanie Briggs, Cleone Wellington, Rebecca Coddington, Yu Gao, Isabella Garti, Sascha Kowalenko, Sarah Ireland, Catherine Austin, John D. Boffa, Marah Prior, Kelsie Kahl, Bettina Chaseling, Sarah Khaw, Emily Armstrong, Donna Hartz, Yvette Roe
Watchful Waiting Compared With Immediate Antibiotics for Urban Aboriginal and Torres Strait Islander Children With Uncomplicated Acute Otitis Media (WATCH): A Non-Inferiority Randomised Controlled Trial
Jennifer S. Reath, Hasantha Gunasekera, Sanja Lujic, Amanda J. Leach, Letitia Campbell, Robyn Walsh, Tim Usherwood, Geoffrey K. Spurling, Claudette A. Tyson, Deborah A. Askew, Kelvin Kong, Chelsea J. Watego, Peter Morris, Wendy Hu, Penelope A. Abbott
Beds Still Burning: Suicide Should Not Be in the Vocabulary of Children
Rudi Louis Taylor-Bragge
Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit?
Troy Walker, Simone Sherriff, Jennifer Browne